Allergy Therapeutics Statistics

Total Valuation

AIM:AGY has a market cap or net worth of GBP 314.59 million. The enterprise value is 332.66 million.

Market Cap	314.59M
Enterprise Value	332.66M

Important Dates

The last earnings date was Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

AIM:AGY has 4.77 billion shares outstanding. The number of shares has increased by 458.41% in one year.

Current Share Class	n/a
Shares Outstanding	4.77B
Shares Change (YoY)	+458.41%
Shares Change (QoQ)	+75.22%
Owned by Insiders (%)	0.19%
Owned by Institutions (%)	3.97%
Float	222.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.48
PB Ratio	84.83
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.27
EV / Sales	6.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.36

Financial Position

The company has a current ratio of 1.63, with a Debt / Equity ratio of 8.35.

Current Ratio	1.63
Quick Ratio	0.93
Debt / Equity	8.35
Debt / EBITDA	n/a
Debt / FCF	-0.87
Interest Coverage	-9.06

Financial Efficiency

Return on equity (ROE) is -1,392.76% and return on invested capital (ROIC) is -58.99%.

Return on Equity (ROE)	-1,392.76%
Return on Assets (ROA)	-32.61%
Return on Invested Capital (ROIC)	-58.99%
Return on Capital Employed (ROCE)	-77.54%
Revenue Per Employee	90,194
Profits Per Employee	-65,712
Employee Count	612
Asset Turnover	0.84
Inventory Turnover	2.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +147.74% in the last 52 weeks. The beta is 1.37, so AIM:AGY's price volatility has been higher than the market average.

Beta (5Y)	1.37
52-Week Price Change	+147.74%
50-Day Moving Average	6.69
200-Day Moving Average	5.61
Relative Strength Index (RSI)	48.97
Average Volume (20 Days)	361,515

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AIM:AGY had revenue of GBP 55.20 million and -40.22 million in losses. Loss per share was -0.01.

Revenue	55.20M
Gross Profit	29.74M
Operating Income	-34.34M
Pretax Income	-39.17M
Net Income	-40.22M
EBITDA	-32.17M
EBIT	-34.34M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 12.92 million in cash and 30.99 million in debt, giving a net cash position of -18.07 million or -0.00 per share.

Cash & Cash Equivalents	12.92M
Total Debt	30.99M
Net Cash	-18.07M
Net Cash Per Share	-0.00
Equity (Book Value)	3.71M
Book Value Per Share	0.00
Working Capital	12.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -32.14 million and capital expenditures -3.40 million, giving a free cash flow of -35.54 million.

Operating Cash Flow	-32.14M
Capital Expenditures	-3.40M
Free Cash Flow	-35.54M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 53.87%, with operating and profit margins of -62.20% and -72.86%.

Gross Margin	53.87%
Operating Margin	-62.20%
Pretax Margin	-70.95%
Profit Margin	-72.86%
EBITDA Margin	-58.27%
EBIT Margin	-62.20%
FCF Margin	n/a

Dividends & Yields

AIM:AGY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-458.41%
Shareholder Yield	-458.41%
Earnings Yield	-12.78%
FCF Yield	-11.30%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AIM:AGY has an Altman Z-Score of -4.01. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.01
Piotroski F-Score	n/a